Goals

Improve management of CR topics

Establish a CR Committee

End of 2011

The CR Committee was founded in 2011. It convened four times in 2011 and 2012.

Establish a globally uniform hazard and risk communication system for all relevant Merck KGaA, Darmstadt, Germany chemicals in the supply chain, incorporating the principles of prevention

Implementation of REACH:

Publish the ScIDeEx® calculation program on our Chemicals portal

End of 2011

The program ScIDeEx®  has been published on our website.

Provide all mixtures with new safety data sheets in accordance with REACH Annex II

End of 2012

All safety data sheets were converted to the new format by the deadline.

Register substances produced in quantities ranging from 100-1,000 metric tons per year (phase 2 of REACH implementation) and register non-phase-in substances

Mid-2013

For more than 75 substances, and thus a majority of the relevant substances, the work has already been done. Merck KGaA, Darmstadt, Germany is on schedule in terms of reaching its goal.

Register substances produced in quantities ranging from 1-100 metric tons per year (phase 3 of REACH implementation) and register non-phase-in substances

Mid-2018

We have started the process of registering substances for phase 3.

Implementation of GHS/CLP:

Classify mixtures and sets according to the CLP regulation

Mid-2015

We have started the process of classifying mixtures.

Implementation of the Global Product Strategy (GPS):

Within the scope of GPS, provide product safety summaries for all hazardous substances registered under REACH

End of 2020

The first product safety summaries are available on the website of the International Council of Chemical Associations (ICCA ). In parallel to the registration of substances for REACH, Merck KGaA, Darmstadt, Germany will produce further product safety summaries in order to achieve the goal for all substances.

Projects for hazard communication:

Update safety data sheets for non-hazardous materials

End of 2020

We have started updating the safety data sheets.

Increase the number of safety data sheets prepared to a globally uniform standard

End of 2020

A Group-wide standard is currently being developed.

Harmonize animal welfare throughout Merck KGaA, Darmstadt, Germany

Establish Group-wide governance for Corporate Animal Science & Welfare

End of 2014

Develop a Group-wide audit concept for contract animal testing facilities

End of 2015

Harmonize the high quality of animal facilities at the prescription medicines division

Obtain AAALAC International accreditation for all prescription medicines division laboratory animal facilities

End of 2015

Further improve warehouse and transport safety

Create a Group-wide standard for safe logistics

End of 2013

Systematically share best warehouse and transport safety practices among employees worldwide

End of 2013

Expand scope of transport safety audits, to include contracted service providers

End of 2014

Develop additional performance indicators to assess warehouse and transport activities

End of 2014

Sustainability in the supply chain

Introduce the new supplier management process within the most important legal entities

End of 2012

A new supplier management process has been instituted in the most important legal entities.

Adapt the general terms and conditions to integrate our Responsible Sourcing Principles into all orders

End of 2013

Conduct CR audits on 30 suppliers with a risk potential

End of 2013

Create the technical prerequisites for obtaining supplier self-disclosures in France, the United States, China, Italy, the United Kingdom, and Ireland by implementing a new computerized supplier management system

End of 2013

Collect supplier self-disclosures from higher-risk suppliers from whom we procure a volume above a defined threshold, in the countries Germany, Brazil, Mexico, Switzerland, Japan, India, France, the United States, China, Italy, the United Kingdom, and Ireland

End of 2013

Introduce a performance management system

Introduce performance management systems for all employees with target agreements, feedback and coaching

End of 2013

In 2012, 98% of employees took part in a performance and development evaluation.

Introduce development plans for all employees with performance evaluations, target agreements, feedback and coaching

End of 2013

By the end of 2012, development plans had been instituted for 77% of employees.

Introduce development plans for all managers from Millipore Corporation, which was acquired in 2010

End of 2011

The Global Grading System was introduced incrementally for the employees of Millipore Corporation, which was acquired in 2010. This process had not yet reached completion as of the end of 2011, which is why the status cannot be specified for the end of 2011. At the end of 2012, development plans were instituted for 85% of the management; this process is to be completed by the end of 2013.

Talent & Succession Management: Fill at least 2/3 of positions at global grade 16+ with internal candidates

Use the Talent & Succession Management Process to identify suitable employees with management potential and define a process to systematically develop employees

Ongoing

In 2011, we intitiated the Performance & Talent Process to systematically develop management. In 2012, 88% of the vacant management positions were filled internally.

Reduce work accidents throughout Merck KGaA, Darmstadt, Germany (lost time injury rate = 2.5)

Implement the BeSafe! program; hold EHS forums on “Safety Behavior Change”

End of 2015

In 2011, we launched the BeSafe! program. Through systematic accident prevention measures (such as training and campaigns to strengthen our corporate safety culture), we attained an LTIR of 2.0 in 2011 and an LTIR of 2.3 in 2012. We are working to lastingly stabilize our LTIR.

Increase the percentage of management positions (Global Grade 14+) held by women to 25%-30%

Increase the percentage of management positions held by women through numerous initiatives that move women into those positions

End of 2016

23% of management positions were held by women in 2011; 24% were held by women in 2012, a 2% increase over 2010.

Obtain ISO 14001:2004 Group certificate

Certify all production sites to ISO 14001:2004;
certify the Millipore sites acquired in July 2010

Ongoing

New production sites were successively added to the Group certificate. Four Millipore production sites are scheduled to be externally certified and added to the Group certificate in 2013.

20% reduction of direct and indirect greenhouse gas emissions (Scope 1 and 2) of Merck KGaA, Darmstadt, Germany (2006 baseline)

Systematically examine the energy consumption at the individual sites

End of 2020

The production plants in Darmstadt and Gernsheim were systematically examined in terms of energy savings potential. In addition to this, energy checks were conducted at the Altdorf, Semoy, Taicang, Savannah, and Eppelheim sites.

Identify and implement potential ways to save energy

End of 2020

Nearly 70 projects to save energy or reduce greenhouse gas emissions have been initiated, and some of them have already reached completion.

Reduce process-related emissions

End of 2020

We have made progress in reducing process-related emissions. Despite increased production volume, we managed to lower emissions slightly.

Eliminate the worm disease schistosomiasis in Africa

Provide tablets containing praziquantel free of charge to treat school children in Africa

Ongoing

More than 100 million tablets were donated from the beginning of the project to the end of 2012. More than 28 million children were treated in total (figure not yet final; figures for 2012 will not be finalized until July 2013). In 2011 and 2012, over seven million children were treated.

2011: 25 million tablets provided to nine countries in Africa

2012: 27 million tablets provided to eight countries in Africa

Run an awareness program to explain the causes of schistosomiasis and potential preventive measures.

End of 2013

Until mid-2012, instructional materials were tested in Senegal and Malawi as part of a pilot project. In 2013, the awareness program will be initiated in both countries, taking into account experience from the pilot projects.

Incrementally increase the number of tablets donated annually by a factor of ten, up to 250 million

End of 2016

Currently searching for additional API suppliers.

Research a new formulation of praziquantel for children under 6 years old

In July 2012, a public-private partnership (PPP) was founded.
Milestone: Preclinical development is to be completed by 2014; clinical development is scheduled to start in 2014.

Optimize the praziquantel formulation

End of 2014

Development of a film coating to make the tablets easier for patients to swallow and to make them even more resistant to long transport times.

Combat counterfeit medicines by providing and further developing the mobile GPHF Minilab

Develop new test methods for five active ingredients and add the descriptions of the new test methods to the user manuals

End of 2011

2011: Seven new test methods were developed.

2012: Five training seminars were conducted on using the GPHF Minilab, and seven new test methods were developed.

Conduct three training seminars on using the GPHF Minilab, sell 50 Minilabs, develop seven new test methods

End of 2013